The treatment of Crohn’s disease has expanded with the development of biologics with different mechanisms of action. Ustekinumab, an inhibitor of IL-23, was approved for use in patients with Crohn’s Disease (CD) in September 2016. We were interested in the sequencing of biologic agents before and after the approval of ustekinumab in CD.